Carillon Tower Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Carillon Tower Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$186M	Buy	2,543,104 +1,033,375	+68%	+$76.8M	1.13%	7
2020 Q3	$117M	Sell	1,509,729 -900,861	-37%	-$62M	1.56%	2
2020 Q2	$134M	Buy	2,410,590 +794,796	+49%	+$34M	1.03%	8
2020 Q1	$48.6M	Buy	1,615,794 +414,850	+35%	+$14M	0.48%	55
2019 Q4	$43.5M	Sell	1,200,944 -604,942	-33%	-$18.5M	0.29%	121
2019 Q3	$49.2M	Hold	1,805,886	–	–	0.34%	98
2019 Q2	$43.4M	Hold	1,805,886	–	–	0.3%	117
2019 Q1	$47.7M	Hold	1,805,886	–	–	0.34%	104
2018 Q4	$35.3M	Hold	1,805,886	–	–	0.3%	124
2018 Q3	$35.4M	Hold	1,805,886	–	–	0.25%	160
2018 Q2	$29.9M	Buy	+1,805,886	New	+$27.5M	0.24%	153

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carillon Tower Advisers's HZNP Position: Q4 2020 in Review

Carillon Tower Advisers increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 68% in Q4 2020, buying an estimated $76.8M and bringing the position to 2,543,104 shares worth $186M. The position accounts for 1.13% of the portfolio, ranked #7.

Carillon Tower Advisers first reported a position in HZNP in Q2 2018 and has held it in 11 quarters since. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

Carillon Tower Advisers held 2,543,104 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $186M as of Q4 2020.
Carillon Tower Advisers bought 1,033,375 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $76.8M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 1.13% of Carillon Tower Advisers's portfolio in Q4 2020, its #7 holding.
Carillon Tower Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2018 and has held it in 11 quarters since.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.